Search company, investor...

Predict your next investment

Venture Capital
dolbyventures.com

Investments

98

Portfolio Exits

18

Funds

1

Partners & Customers

1

About Dolby Family Ventures

Dolby Family Ventures is an early stage venture firm focused on building great technology companies. The firm partners with best-in-class innovators and strong investment syndicate partners at the seed stage of a company's development. The fund honors the legacy of Ray Dolby and his commitment to engineers and their vision to solve the world's toughest problems. Dolby Family Ventures formalizes the Dolby family's ongoing multi-generational commitment to supporting talented entrepreneurs.

Headquarters Location

999 Brannan Street Suite 114

San Francisco, California, 94103,

United States

415-449-1005

Want to inform investors similar to Dolby Family Ventures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Dolby Family Ventures News

Genemod: $4.5 Million Secured For Workspace Collaboration Platform

May 9, 2023

Genemod – a cloud-based workspace collaboration software for biopharma R&D teams – announced it raised $4.5 million in seed funding co-led by defy.vc and LDV Partners with participation from Dolby Family Ventures and Vulcan/Cercano Ventures. Over the past year, Genemod has expanded into the biopharma R&D space working with teams from startups to enterprise companies including AstraZeneca, Bristol-Myers, Merck, and more. And working across siloed spreadsheets, updating data in real-time, and collaborating on projects in disparate geographical locations are just several examples of how teams using Genemod are able to eliminate busywork and other barriers so they can focus on developments in biopharma. The legacy R&D software and other traditional methods are decentralized, disorganized, and inefficient, resulting in higher healthcare costs. And Genemod is working to be the solution to this problem by building a dynamic cloud-based research platform designed for research teams to house their entire R&D lifecycle: from data acquisition and project documentation to inventory management and reporting. The intuitive interface enables users to easily visualize their data and track progress and updates – including what changes are made by whom. Genemod is known for working to solve the reproducibility crisis – which is an ongoing phenomenon that continues to throw off research scientists. Reproducibility is essentially the ability to recreate the same experiment to achieve the same results. While this could sound simple in theory, disorganized data and a chronic lack of cloud-based organizational tools (among other issues) mean that experiment results continue to be inconsistent, costing the US government and researchers billions per year. Discovery and clinical translation are no longer driven by siloed one-off experimentation but compounding from accelerating gains in scale of data, reproducibility, and fidelity of experiment. The COVID-19 pandemic played a major role in accelerating Genemod’s innovation and development with Genemod playing an important role in aiding pandemic-related research. And the pandemic overall led to collaboration between an increasing number of companies and research teams in a variety of industries. This includes the pharmaceutical and biotech business, which are leaning into dynamic, market-driven solutions in order to meet ever-increasing global healthcare and environmental challenges. KEY QUOTES: “We believe that scientists must be empowered with tools to discover and develop medicines and ultimately get them to market faster than ever before. That’s why we built Genemod – to transform the way biopharma companies operate.” — Jacob Lee, CEO and Co-founder of Genemod “Genemod aims to be the go-to standard for research scientists just as how designers use Figma and engineers use Jira.” — Jin Choe, Co-founder at Genemod “Biotechnology is one of the fastest growing industries in existence, and the software that powers efficiency and communication in labs has the potential to radically transform the world. Genemod is positioned to solve some of the world’s most pressing problems in the coming decades, from pandemics and other diseases to climate change. We are pleased to be investing in this great team and company and look forward to partnering with them as they continue to scale and grow.” — Neil Sequeira, Founder and Partner at defy.vc Trending on Pulse 2.0

Dolby Family Ventures Investments

98 Investments

Dolby Family Ventures has made 98 investments. Their latest investment was in Paradromics as part of their Series A on May 5, 2023.

CBI Logo

Dolby Family Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/18/2023

Series A

Paradromics

$33M

No

6

5/4/2023

Seed VC - II

Genemod

$4.5M

Yes

8

4/12/2023

Unattributed VC

Kebotix

$2.21M

Yes

2

4/5/2023

Series D

Subscribe to see more

$99M

Subscribe to see more

10

3/20/2023

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/18/2023

5/4/2023

4/12/2023

4/5/2023

3/20/2023

Round

Series A

Seed VC - II

Unattributed VC

Series D

Seed VC - II

Company

Paradromics

Genemod

Kebotix

Subscribe to see more

Subscribe to see more

Amount

$33M

$4.5M

$2.21M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

8

2

10

10

Dolby Family Ventures Portfolio Exits

18 Portfolio Exits

Dolby Family Ventures has 18 portfolio exits. Their latest portfolio exit was Tempo Automation on November 23, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/23/2022

Reverse Merger

$99M

4

12/10/2021

Acquired

$99M

2

10/8/2021

IPO

$99M

Public

4

8/10/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/26/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/23/2022

12/10/2021

10/8/2021

8/10/2021

6/26/2021

Exit

Reverse Merger

Acquired

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

4

2

4

10

10

Dolby Family Ventures Fund History

1 Fund History

Dolby Family Ventures has 1 fund, including Dolby Family Ventures.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/16/2014

Dolby Family Ventures

1

Closing Date

6/16/2014

Fund

Dolby Family Ventures

Fund Type

Status

Amount

Sources

1

Dolby Family Ventures Partners & Customers

1 Partners and customers

Dolby Family Ventures has 1 strategic partners and customers. Dolby Family Ventures recently partnered with Gladstone Institutes, and Evotec SE on July 7, 2015.

Date

Type

Business Partner

Country

News Snippet

Sources

7/23/2015

Partner

United States, and Germany

Article | By Dana G. Smith, PhD | July 23, 2015. The Gladstone Institutes Launches Novel Partnership with Dolby Family Ventures and Evotec AG

David Dolby , Managing Director , Dolby Family Ventures , joined forces with Gladstone Institute of Neurological Disease because its research has great potential to change the progression of Alzheimer 's disease .

1

Date

7/23/2015

Type

Partner

Business Partner

Country

United States, and Germany

News Snippet

Article | By Dana G. Smith, PhD | July 23, 2015. The Gladstone Institutes Launches Novel Partnership with Dolby Family Ventures and Evotec AG

David Dolby , Managing Director , Dolby Family Ventures , joined forces with Gladstone Institute of Neurological Disease because its research has great potential to change the progression of Alzheimer 's disease .

Sources

1

Dolby Family Ventures Team

3 Team Members

Dolby Family Ventures has 3 team members, including current Senior Managing Director, Pascal N. Levensohn.

Name

Work History

Title

Status

Pascal N. Levensohn

Senior Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Pascal N. Levensohn

Subscribe to see more

Subscribe to see more

Work History

Title

Senior Managing Director

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.